Literature DB >> 8978593

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro.

Y Wakahara1, A Nawa, T Okamoto, A Hayakawa, F Kikkawa, N Suganama, F Wakahara, Y Tomoda.   

Abstract

To clarify the significance of the Fas antigen (Ag) in gynecologic tumors, its expression in gynecologic cancer cell lines was examined. The Fas Ag was expressed in 6 of 15 cell lines. Five of 8 ovarian cancer cell lines but none of 4 choriocarcinoma cell lines expressed the Fas Ag. In drug-resistant cell lines derived from one of the Fas-positive cells, its expression was not lost after development of resistance to cisplatin, SN-38 or etoposide, but its expression was absent in the cell line resistant to Adriamycin. The effect of the anti-Fas antibody (Ab) was then studied. Apoptosis was induced in 7 of 9 Fas-positive cell lines, whereas the remaining two cell lines were unaffected. Furthermore, the combination effect of the anti-Fas Ab and drugs was examined in an ovarian cancer cell line and its drug-resistant variants, and a synergistic effect was observed. These results suggest important roles of the Fas Ag in ovarian cancer and the potential for overcoming drug resistance by a combination of the anti-Fas Ab and various drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978593     DOI: 10.1159/000227661

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  2 in total

1.  SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling.

Authors:  Vinicius Souza; Yan Bin Dong; H Sam Zhou; Wolfgang Zacharias; Kelly M McMasters
Journal:  J Transl Med       Date:  2005-12-23       Impact factor: 5.531

2.  Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms.

Authors:  S Munakata; T Enomoto; M Tsujimoto; Y Otsuki; H Miwa; H Kanno; K Aozasa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.